<i>BRAF</i> V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
<i>Background and Objectives: BRAF</i> mutational status in resected non-small cell lung cancer (NSCLC) in the Korean population is poorly understood. We explored <i>BRAF</i> (particularly <i>BRAF</i> V600E) mutational status among Korean patients with NSCLC. <...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/6/1085 |
| Summary: | <i>Background and Objectives: BRAF</i> mutational status in resected non-small cell lung cancer (NSCLC) in the Korean population is poorly understood. We explored <i>BRAF</i> (particularly <i>BRAF</i> V600E) mutational status among Korean patients with NSCLC. <i>Materials and Methods</i>: This study included 378 patients with resected primary NSCLC who were enrolled from January 2015 to December 2017. The authors obtained formalin-fixed paraffin-embedded (FFPE) tissue blocks and performed peptide nucleic acid (PNA)-clamping polymerase chain reaction (PCR) for detecting BRAF V600, real-time PCR for detecting <i>BRAF</i> V600E, and immunohistochemical analyses using the mutation-specific Ventana VE1 monoclonal antibody. For positive cases in any methods mentioned above, direct Sanger sequencing was additionally performed. <i>Results:</i> The PNA-clamping method revealed the <i>BRAF</i> V600 mutation in 5 (1.3%) of the 378 patients. Among these five patients, real-time PCR, direct Sanger sequencing detected <i>BRAF</i> V600E mutations in three (0.8%) patients. Thus, two cases showed differences in their PNA-clamping and the others. Direct Sanger sequencing of PNA-clamping PCR product was performed for two cases showing negative results on direct Sanger sequencing; both contained <i>BRAF</i> mutations other than V600E. All patients harboring <i>BRAF</i> mutations had adenocarcinomas, and all patients with V600E mutation exhibited minor micropapillary components. <i>Conclusions</i>: Despite the low incidence of the <i>BRAF</i> mutation among Korean patients with NSCLC, lung adenocarcinoma patients with micropapillary components should be prioritized in terms of <i>BRAF</i> mutation testing. Immunohistochemical staining using Ventana VE1 antibody may serve as a screening examination for <i>BRAF</i> V600E. |
|---|---|
| ISSN: | 1010-660X 1648-9144 |